Mr. Boms has more than 20 years of experience in leadership, management and commercialization of innovative medical devices in the area of interventional cardiology and urology. In 1991, Mr. Boms founded DDM (Diseno y Desarrollo Medico S.A de C.V). DDM is a high-tech medical device company focused on providing superior services in Latin America. DDM currently serves more than 70 cath labs and over 300 interventional cardiologists who serve the Mexican population of approximately 100 million people. Mr. Boms and DDM aim to help people heal people, and in the early 90’s he launched a unique educational program. The program included technical procedural training and support, sharing the clinical experience of practiced physicians with the Latin American interventional cardiology market. Mr. Boms also assisted in the creation of the society for interventional cardiology called SOLACI, Sociedad Latinoamericana De Cardiologia Intervecionista.
Fausto have 24 years of experience at DDM group in Mexico as a medical devices expert serving the private and public healthcare institutions. the group is specialising in Cardiology, Radiology, Neuroradiology and Spine Surgery.
In 2015 he became a member of the Board of Directors for Cardia, Inc., a company specialised in percutaneous closure of ASD’s (Atrial Septal Defect) and PFO’s (Patent Foramen Ovale) devices.
In 1999 Fausto was appointed as the CEO of DDM’s group. Since then , he founded several nationwide branches in Monterrey, Guadalajara, San Luís Potosí, Hermosillo among others.
Fausto launched advanced High quality technology in Mexico and managed clinical protocols for products which received Ministry of Health registration leading to FDA approval.
Liat is a partner at SKY, one of the leading private equity funds in Israel. Liat also serves as a board member in Spectronix ltd, E. Schnapp & co. works ltd and Elspec engineering ltd, as well as in other portfolio companies of the fund .Prior to joining SKY, Liat served as a senior business consultant at Swary-Yochman and ahead of that worked on the Israeli desk at PwCs Global Capital Markets Group.Liat was a faculty member at the Leon Recanati School of Management at Tel Aviv University, where she taught several courses in financial accounting. Liat is a licensed CPA and holds a B.Sc in Statistics, Operations Research and Accounting from Tel Aviv University.
Mr. Ben David serves as the Managing Director at AKUM – The Israeli producers and compositors copyright organization.
Ms. Rafaeli is considered one of the top Israeli experts in her field, possessing many years of experience in all aspects of media legislation and other legal aspects, public broadcasting, regulation and content issues. Ms. Rafaeli is a senior member of management at YES, in charge of all regulatory issues and responsible for all channels acquisitions. During 1998, Ms. Rafaeli acted as an independent consultant to some of the most prominent companies and institutions in Israel, including Bezeq, the Anti Trust Commission, Channel 2, TAIA Communications, The Israel Institute of Democracy, and the Ministry of Tourism.
Previously, Ms. Rafaeli held the position of Chairperson of the Cable and Satellite Council in the Ministry of Communications. She was a founder and a member of the Israeli Rating Committee and the Chairperson of the Support Committee for local broadcasts and original production. She also founded the Cable Original Production Fund. Ms. Rafaeli also served as the Senior Communications and Broadcasting Consultant to the Minister of Culture and Education, Shulamit Aloni between 1989-1992. Ms. Rafaeli joined the new cable operator ( MOC) in Israel (Golden Channels) and founded a section for press regulation and community relations. Ms. Rafaeli also edited the first TV guide published in Israel. Ms. Rafaeli holds a Bachelor’s degree in in History of Art and Theatre from The Hebrew University in Jerusalem and has also studied Political Science in Tel Aviv University.
Mr. Grossman joined our board of directors in January 2015. His business experience includes venture capital, private equity and executive management, mainly in the healthcare arena. Mr. Grossman currently serves as Chairman of the Board at Algomizer Ltd. (TASE: ALMO) and as external director at Cellect Biomed Ltd. (TASE: CLBD). Previously Mr. Grossman was a Director and the CEO at XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL), a late stage drug development company focused on Lupus, Multiple Myeloma and Schizophrenia. Prior to that Mr. Grossman was VP at Eurocom Investments, and Senior Analyst at Israel Health Care Ventures (IHCV). Over the years, Mr. Grossman has also served as director in several other public companies, including ones traded on AIM and TASE.